MAPT and Alzheimer disease: These data suggest that interrogation of antemortem CSF in cognitively impaired individuals to determine levels of t-tau, p-tau, and Aβ42, together with MRI and amyloid imaging biomarkers, could replace autopsy confirmation of AD plaque and tangle pathology as the “gold standard” for the diagnosis of definite AD in the near future [101].